RT Journal Article
SR Electronic
T1 Determinants of high residual post-PCV13 pneumococcal vaccine type carriage in Blantyre, Malawi: a modelling study
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 477695
DO 10.1101/477695
A1 J. Lourenço
A1 U. Obolski
A1 T.D. Swarthout
A1 A. Gori
A1 N. Bar-Zeev
A1 D. Everett
A1 A.W. Kamng’ona
A1 T.S. Mwalukomo
A1 A.A. Mataya
A1 C. Mwansambo
A1 M. Banda
A1 S. Gupta
A1 N. French
A1 R.S. Heyderman
YR 2019
UL http://biorxiv.org/content/early/2019/07/26/477695.abstract
AB Background In November 2011, Malawi introduced the 13-valent pneumococcal conjugate vaccine (PCV13) into the routine infant schedule. Four to seven years after introduction (2015-2018), rolling prospective nasopharyngeal carriage surveys were performed in the city of Blantyre. Carriage of Streptococcus pneumoniae vaccine serotypes (VT) remained higher than reported in developed countries, and VT impact was surprisingly asymmetric across age-groups. A dynamic transmission model was fit to survey data using a Bayesian Markov-chain Monte Carlo approach, to obtain insights into the determinants of post-PCV13 age-specific VT carriage.Results Accumulation of naturally acquired immunity with age and age-specific transmission potential were both key to reproducing the observed data. VT carriage reduction peaked sequentially over time, earlier in younger and later in older age-groups. Estimated vaccine efficacy (protection against carriage) was 66.87% (95% CI 50.49-82.26%), similar to previous estimates. Ten-year projected vaccine impact (VT carriage reduction) among 0-9 years old was lower than observed in other settings, at 76.23% (CI 95% 68.02-81.96%), with sensitivity analyses demonstrating this to be mainly driven by a high local force of infection.Conclusions We have identified both vaccine-related and host-related determinants of post-PCV13 pneumococcal VT transmission in Blantyre with vaccine impact determined by age-related characteristics of the local force of infection. These findings are likely to be generalisable to other Sub-Saharan African countries in which PCV impact has been lower than desired, and have implications for the interpretation of post-PCV carriage studies and future vaccination programs.VTvaccine typeNVTnon-vaccine typePCVpneumococcal conjugate vaccineCIconfidence intervalbMCMCBayesian Markov chain Monte CarloODEordinary-differential equationsFOIforce of infectiondVPduration of vaccine-induced protection